Psyence Biomed Initiates Patient Dosing
Ticker: PBM · Form: 6-K · Filed: Apr 23, 2026 · CIK: 0001985062
Sentiment: neutral
Topics: clinical-trial, press-release, biotech
TL;DR
Psyence Biomed starts patient dosing, check the press release for details.
AI Summary
Psyence Biomedical Ltd. filed a Form 6-K on April 23, 2026, reporting a press release titled "PSYENCE BIOMED INITIATES PATIENT DO". The filing includes the press release as Exhibit 99.1 and the complete submission text file.
Why It Matters
This filing indicates a significant step in Psyence Biomedical's clinical trials, potentially moving their drug candidates closer to market approval.
Risk Assessment
Risk Level: medium — Clinical trial initiations carry inherent risks related to trial success, regulatory approval, and market adoption.
Key Players & Entities
- PSYENCE BIOMED LTD. (company) — Filer
- PSYENCE BIOMED (company) — Company mentioned in press release title
FAQ
What is the specific title of the press release filed by Psyence Biomedical Ltd.?
The press release is titled "PSYENCE BIOMED INITIATES PATIENT DO".
What form was filed by Psyence Biomedical Ltd. on April 23, 2026?
Psyence Biomedical Ltd. filed a Form 6-K.
What is the SEC Accession Number for this filing?
The SEC Accession Number is 0001213900-26-047089.
What is the CIK number for Psyence Biomedical Ltd.?
The CIK number for Psyence Biomedical Ltd. is 0001985062.
What is the SIC code associated with Psyence Biomedical Ltd.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 23, 2026 regarding PSYENCE BIOMEDICAL LTD. (PBM).